⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

February 2, 2026BMC CancerOpen Access

Impact of proton pump inhibitor use on immune-related adverse events in patients with non-small cell lung cancer: a retrospective study

Ippei Miyamoto Tetsuo Shimizu Mizuki Hanamura Ryoma Tanaka Ryo Kusahana Masayuki Nomoto Kenichi Sugaya Yoshiko Nakagawa Yasuhiro Gon

View Full Paper

Ask AI

Bookmark

Share

Key Points

The research aims to investigate the relationship between proton pump inhibitor use and the occurrence of immune-related adverse events in lung cancer patients.
Conducted a retrospective study analyzing patient records.
Examined the incidence of immune-related adverse events (irAEs) associated with proton pump inhibitors.
Evaluated the influence of gut microbiome changes on irAE occurrence.
PPI use was linked to a lower incidence of non-CIP immune-related adverse events.
No significant effect of PPI was noted for CIP-related adverse events.
PPI use was not identified as an independent prognostic factor for irAE occurrence.

Implication

Retrospective study reveals PPI use may lower non-CIP irAE incidence in lung cancer, suggesting complex interactions.

Abstract

No abstract yet. The journal hasn't published one we can show.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Miyamoto et al. (2026) studied this question.

synapsesocial.com/papers/69843360f1d9ada3c1fb0853 https://doi.org/10.1186/s12885-026-15646-7

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1The impact of proton-pump inhibitor use on the incidence and severity of gastrointestinal toxicity to checkpoint inhibition.2024
2Impact of proton pump inhibitors on immunotherapy is modulated by prior chemotherapy and linked to gut microbiome–immune cell signaturesCohort Study · 2026 · 2 citations
3Impact of Concomitant Proton Pump Inhibitor Use on the Efficacy of Immune Checkpoint Inhibitors Across Multiple Cancer Types2025 · 6 citations
4A39-12 Proton Pump Inhibitor Use and Impact on Mortality and Clinical Outcomes in Idiopathic Pulmonary Fibrosis: A Propensity-Matched Cohort StudyCohort Study · 2026
5Impact of Proton Pump Inhibitors on Immune-related Adverse Events and Efficacy During Pembrolizumab MonotherapyOriginal Research · 2026

More related papers

Impact of proton pump inhibitors and antibiotics on survival in immunotherapy treated gastrointestinal cancers.2026
Proton pump inhibitor use and overall survival in patients with gastric adenocarcinoma treated with first-line immunotherapy: A real-world pharmacoepidemiologic study.2026
Associations of proton pump inhibitors with susceptibility to influenza, pneumonia, and COVID-19: Evidence from a large population based cohort study2024

More from BMC Cancer

Research on the construction of a skill model of lung cancer caregivers based on grounded theorySat,
Neoadjuvant immunochemotherapy and pathological response in locally advanced cervical cancer: a real-world bicenter cohort studyFri,